US3480613A
(en)
|
1967-07-03 |
1969-11-25 |
Merck & Co Inc |
2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
HU196714B
(en)
|
1984-10-04 |
1989-01-30 |
Monsanto Co |
Process for producing non-aqueous composition comprising somatotropin
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
PH30995A
(en)
|
1989-07-07 |
1997-12-23 |
Novartis Inc |
Sustained release formulations of water soluble peptides.
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
US5026687A
(en)
|
1990-01-03 |
1991-06-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
|
WO1991015516A2
(en)
|
1990-04-06 |
1991-10-17 |
Genelabs Incorporated |
Hepatitis c virus epitopes
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
DE4207363A1
(de)
|
1992-03-04 |
1993-09-09 |
Max Delbrueck Centrum |
Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung
|
US5610054A
(en)
|
1992-05-14 |
1997-03-11 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic RNA molecule targeted against Hepatitis C virus
|
AU680435B2
(en)
|
1992-09-10 |
1997-07-31 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US6391542B1
(en)
|
1992-09-10 |
2002-05-21 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus-associated diseases
|
US6433159B1
(en)
|
1992-09-10 |
2002-08-13 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus associated diseases
|
US6995146B2
(en)
|
1992-09-10 |
2006-02-07 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US6174868B1
(en)
|
1992-09-10 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US6423489B1
(en)
|
1992-09-10 |
2002-07-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus-associated diseases
|
TW333456B
(en)
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
EP0686043B1
(en)
|
1993-02-24 |
1999-06-23 |
WANG, Jui, H. |
Compositions and methods of application of reactive antiviral polymers
|
US6087324A
(en)
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
AU688344B2
(en)
|
1993-07-19 |
1998-03-12 |
Mitsubishi-Tokyo Pharmaceuticals, Inc. |
Hepatitis C virus proliferation inhibitor
|
DE4415539C2
(de)
|
1994-05-03 |
1996-08-01 |
Osama Dr Dr Med Omer |
Pflanzen mit virustatischer und antiviraler Wirkung
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
DE4432623A1
(de)
|
1994-09-14 |
1996-03-21 |
Huels Chemische Werke Ag |
Verfahren zur Bleichung von wäßrigen Tensidlösungen
|
GB9505025D0
(en)
|
1995-03-13 |
1995-05-03 |
Medical Res Council |
Chemical compounds
|
JP3786447B2
(ja)
|
1995-03-31 |
2006-06-14 |
エーザイ株式会社 |
C型肝炎の予防・治療剤
|
EP0835101B1
(en)
|
1995-06-27 |
2004-06-09 |
Takeda Chemical Industries, Ltd. |
Method of producing sustained-release preparation
|
TW448055B
(en)
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
JP2909418B2
(ja)
|
1995-09-18 |
1999-06-23 |
株式会社資生堂 |
薬物の遅延放出型マイクロスフイア
|
US5980945A
(en)
|
1996-01-16 |
1999-11-09 |
Societe De Conseils De Recherches Et D'applications Scientifique S.A. |
Sustained release drug formulations
|
WO1997032018A2
(en)
|
1996-02-29 |
1997-09-04 |
Immusol, Inc. |
Hepatitis c virus ribozymes
|
US5633388A
(en)
|
1996-03-29 |
1997-05-27 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
US5830905A
(en)
|
1996-03-29 |
1998-11-03 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
US5990276A
(en)
|
1996-05-10 |
1999-11-23 |
Schering Corporation |
Synthetic inhibitors of hepatitis C virus NS3 protease
|
US5891874A
(en)
|
1996-06-05 |
1999-04-06 |
Eli Lilly And Company |
Anti-viral compound
|
US6264970B1
(en)
|
1996-06-26 |
2001-07-24 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
US5837257A
(en)
|
1996-07-09 |
1998-11-17 |
Sage R&D |
Use of plant extracts for treatment of HIV, HCV and HBV infections
|
GB9617177D0
(en)
|
1996-08-15 |
1996-09-25 |
Kvaerner H & G Offshore Ltd |
Downhole valve actuation
|
US6419961B1
(en)
|
1996-08-29 |
2002-07-16 |
Takeda Chemical Industries, Ltd. |
Sustained release microcapsules of a bioactive substance and a biodegradable polymer
|
JP3927630B2
(ja)
|
1996-09-27 |
2007-06-13 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウイルス感染症の予防・治療剤
|
US5922757A
(en)
|
1996-09-30 |
1999-07-13 |
The Regents Of The University Of California |
Treatment and prevention of hepatic disorders
|
CA2217134A1
(en)
|
1996-10-09 |
1998-04-09 |
Sumitomo Pharmaceuticals Co., Ltd. |
Sustained release formulation
|
IN183120B
(es)
|
1996-10-18 |
1999-09-11 |
Vertex Pharma |
|
DK0839525T3
(da)
|
1996-10-31 |
2004-11-29 |
Takeda Pharmaceutical |
Præparat med forlænget frigivelse
|
GB9623908D0
(en)
|
1996-11-18 |
1997-01-08 |
Hoffmann La Roche |
Amino acid derivatives
|
IL119833A
(en)
|
1996-12-15 |
2001-01-11 |
Lavie David |
Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
|
ATE233088T1
(de)
|
1996-12-20 |
2003-03-15 |
Takeda Chemical Industries Ltd |
Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
|
US5891474A
(en)
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
US6004933A
(en)
|
1997-04-25 |
1999-12-21 |
Cortech Inc. |
Cysteine protease inhibitors
|
GB9708611D0
(en)
|
1997-04-28 |
1997-06-18 |
Univ Cardiff |
Chemical compounds
|
PL193237B1
(pl)
|
1997-06-30 |
2007-01-31 |
Merz Pharma Gmbh & Co Kgaa |
Pochodne 1-aminoalkilocykloheksanu, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie
|
US6143715A
(en)
|
1997-08-11 |
2000-11-07 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C inhibitor peptide analogues
|
DK1058686T3
(da)
|
1998-02-25 |
2007-03-05 |
Univ Emory |
2'-fluornukleosider
|
US6613358B2
(en)
|
1998-03-18 |
2003-09-02 |
Theodore W. Randolph |
Sustained-release composition including amorphous polymer
|
GB9806815D0
(en)
|
1998-03-30 |
1998-05-27 |
Hoffmann La Roche |
Amino acid derivatives
|
KR19990085365A
(ko)
|
1998-05-16 |
1999-12-06 |
허영섭 |
지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
|
US6833361B2
(en)
|
1998-05-26 |
2004-12-21 |
Ribapharm, Inc. |
Nucleosides having bicyclic sugar moiety
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
GB9821058D0
(en)
|
1998-09-28 |
1998-11-18 |
Univ Cardiff |
Chemical compound
|
WO2000047591A1
(en)
|
1999-02-12 |
2000-08-17 |
Glaxo Group Limited |
Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
WO2001032153A2
(en)
|
1999-11-04 |
2001-05-10 |
Shire Biochem Inc. |
Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
|
CN1427722A
(zh)
|
2000-02-18 |
2003-07-02 |
希拉生物化学股份有限公司 |
用核苷类似物治疗或预防黄病毒感染的方法
|
KR20100003313A
(ko)
|
2000-04-13 |
2010-01-07 |
파마셋 인코포레이티드 |
간염 바이러스 감염 치료를 위한 3'- 또는 2'-하이드록시메틸 치환된 뉴클레오시드 유도체
|
GB0009486D0
(en)
|
2000-04-17 |
2000-06-07 |
Univ Cardiff |
Chemical compounds
|
GB0011203D0
(en)
|
2000-05-09 |
2000-06-28 |
Univ Cardiff |
Chemical compounds
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
EP1736478B1
(en)
|
2000-05-26 |
2015-07-22 |
IDENIX Pharmaceuticals, Inc. |
Methods and compositions for treating flaviviruses and pestiviruses
|
AR034127A1
(es)
|
2000-07-21 |
2004-02-04 |
Schering Corp |
Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
|
US20020068702A1
(en)
|
2000-07-21 |
2002-06-06 |
Marguerita Lim-Wilby |
Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
|
JP4452441B2
(ja)
|
2000-07-21 |
2010-04-21 |
シェーリング コーポレイション |
C型肝炎ウイルスのns3−セリンプロテアーゼ阻害剤としての新規ペプチド
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
US20030008841A1
(en)
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
CN1133642C
(zh)
|
2000-10-09 |
2004-01-07 |
清华大学 |
核苷5’-硫代磷酰氨基酸酯化合物
|
CN1646141B
(zh)
|
2000-10-18 |
2014-06-25 |
吉利德制药有限责任公司 |
用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
|
CN100391967C
(zh)
|
2000-11-20 |
2008-06-04 |
布里斯托尔-迈尔斯斯奎布公司 |
丙型肝炎三肽抑制剂
|
HUP0303436A2
(hu)
|
2000-12-12 |
2004-01-28 |
Schering Corp. |
Diaril-peptidek mint a hepatitis C vírus NS3-szerin proteáz inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
|
AU2002230764A1
(en)
|
2000-12-13 |
2002-06-24 |
Bristol-Myers Squibb Pharma Company |
Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
|
US6653295B2
(en)
|
2000-12-13 |
2003-11-25 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus NS3 protease
|
AU2002230763A1
(en)
|
2000-12-13 |
2008-01-03 |
Bristol-Myers Squibb Pharma Company |
Inhibitors of hepatitis c virus ns3 protease
|
BR0116221A
(pt)
|
2000-12-15 |
2005-09-13 |
Pharmasset Ltd |
Agentes antivirais para tratamento de infecções por flaviviridae
|
US7105499B2
(en)
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
US8481712B2
(en)
|
2001-01-22 |
2013-07-09 |
Merck Sharp & Dohme Corp. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
KR100828453B1
(ko)
|
2001-01-22 |
2008-05-13 |
머크 앤드 캄파니 인코포레이티드 |
Rna 의존성 rna 바이러스 폴리머라제의억제제로서의 뉴클레오시드 유도체
|
NZ540956A
(en)
|
2001-03-01 |
2007-01-26 |
Pharmasset Inc |
Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides
|
WO2003070750A2
(en)
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc |
Rna interference mediated inhibition of hepatitis c virus
|
US20040209831A1
(en)
|
2002-02-20 |
2004-10-21 |
Mcswiggen James |
RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
|
GB0112617D0
(en)
|
2001-05-23 |
2001-07-18 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
GB0114286D0
(en)
|
2001-06-12 |
2001-08-01 |
Hoffmann La Roche |
Nucleoside Derivatives
|
US20050009775A1
(en)
|
2001-06-21 |
2005-01-13 |
Howes Peter David |
Nucleoside compounds in hcv
|
US7022323B2
(en)
|
2001-06-26 |
2006-04-04 |
Progenics Pharmaceuticals, Inc. |
Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
|
EP1435974A4
(en)
|
2001-09-28 |
2006-09-06 |
Idenix Cayman Ltd |
METHOD AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS WITH 4'-MODIFIED NUCLEOSIDES
|
WO2003026675A1
(en)
|
2001-09-28 |
2003-04-03 |
Idenix (Cayman) Limited |
Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
|
US6867185B2
(en)
|
2001-12-20 |
2005-03-15 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
CA2370396A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
CA2369970A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
WO2003068244A1
(en)
|
2002-02-13 |
2003-08-21 |
Merck & Co., Inc. |
Methods of inhibiting orthopoxvirus replication with nucleoside compounds
|
CA2477741A1
(en)
|
2002-02-28 |
2003-09-04 |
Biota, Inc. |
Nucleotide mimics and their prodrugs
|
WO2003099316A1
(en)
|
2002-05-20 |
2003-12-04 |
Bristol-Myers Squibb Company |
Heterocyclicsulfonamide hepatitis c virus inhibitors
|
AU2003299519A1
(en)
|
2002-05-20 |
2004-05-04 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
US6878722B2
(en)
|
2002-05-20 |
2005-04-12 |
Bristol-Myers Squibb Company |
Substituted cycloalkyl P1′ hepatitis C virus inhibitors
|
WO2003100017A2
(en)
|
2002-05-24 |
2003-12-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
EP1515971A2
(en)
|
2002-06-17 |
2005-03-23 |
Merck & Co., Inc. |
Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
AU2003269890A1
(en)
|
2002-06-21 |
2004-01-06 |
Isis Pharmaceuticals, Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
EP1572945A2
(en)
|
2002-06-27 |
2005-09-14 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
JP5087211B2
(ja)
|
2002-06-28 |
2012-12-05 |
イデニクス(ケイマン)リミテツド |
フラビウィルス感染治療のための2′および3′−ヌクレオシドプロドラッグ
|
NZ537662A
(en)
|
2002-06-28 |
2007-10-26 |
Idenix Cayman Ltd |
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
AU2003247084B9
(en)
|
2002-06-28 |
2018-07-26 |
Centre National De La Recherche Scientifique |
Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
|
BR0312278A
(pt)
|
2002-06-28 |
2007-06-19 |
Idenix Cayman Ltd |
éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
WO2004007512A2
(en)
|
2002-07-16 |
2004-01-22 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
US7323449B2
(en)
|
2002-07-24 |
2008-01-29 |
Merck & Co., Inc. |
Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
US20040067877A1
(en)
|
2002-08-01 |
2004-04-08 |
Schinazi Raymond F. |
2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
|
US20040229840A1
(en)
|
2002-10-29 |
2004-11-18 |
Balkrishen Bhat |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
RU2005118421A
(ru)
|
2002-11-15 |
2006-01-20 |
Айденикс (Кайман) Лимитед (Ky) |
2'-разветвленные нуклеозиды и мутация flaviviridae
|
TWI332507B
(en)
|
2002-11-19 |
2010-11-01 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
CA2509687C
(en)
|
2002-12-12 |
2012-08-14 |
Idenix (Cayman) Limited |
Process for the production of 2'-branched nucleosides
|
US7601709B2
(en)
|
2003-02-07 |
2009-10-13 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic hepatitis C serine protease inhibitors
|
AR043006A1
(es)
|
2003-02-12 |
2005-07-13 |
Merck & Co Inc |
Proceso para preparar ribonucleosidos ramificados
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
EP2359833A1
(en)
|
2003-04-25 |
2011-08-24 |
Gilead Sciences, Inc. |
Antiviral phosphonate analogs
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
US7300924B2
(en)
|
2003-04-25 |
2007-11-27 |
Gilead Sciences, Inc. |
Anti-infective phosphonate analogs
|
EP1656093A2
(en)
|
2003-05-14 |
2006-05-17 |
Idenix (Cayman) Limited |
Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
|
WO2005020885A2
(en)
|
2003-05-21 |
2005-03-10 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
|
PT3521297T
(pt)
|
2003-05-30 |
2022-03-18 |
Gilead Pharmasset Llc |
Análogos de nucleosídeo fluorados modificados
|
JP2006527719A
(ja)
|
2003-06-19 |
2006-12-07 |
エフ.ホフマン−ラ ロシュ アーゲー |
4’−アジドヌクレオシド誘導体の調製方法
|
GB0317009D0
(en)
|
2003-07-21 |
2003-08-27 |
Univ Cardiff |
Chemical compounds
|
US20050043266A1
(en)
|
2003-07-25 |
2005-02-24 |
Sumedha Jayasena |
Short interfering RNA as an antiviral agent for hepatitis C
|
KR20060130027A
(ko)
|
2003-10-10 |
2006-12-18 |
버텍스 파마슈티칼스 인코포레이티드 |
세린 프로테아제, 특히 hcv ns3-ns4a 프로테아제의억제제
|
GB0401088D0
(en)
|
2004-01-19 |
2004-02-18 |
Univ Cardiff |
Phosphoramidate derivatives
|
BRPI0508428A
(pt)
|
2004-03-04 |
2007-07-24 |
Leuven K U Res & Dev |
fosfonato nucleosìdeos utilizáveis como ingredientes ativos em composições farmacêuticas para o tratamento de infecções virais e intermediários para sua produção
|
US7534767B2
(en)
|
2004-06-15 |
2009-05-19 |
Merck & Co., Inc. |
C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
|
AU2005256963A1
(en)
|
2004-06-23 |
2006-01-05 |
Centre National De La Recherche Scientifique |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
JP5080973B2
(ja)
|
2004-06-24 |
2012-11-21 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Rna依存性rnaウイルスの感染を処置するためのヌクレオシドアリールホスホルアミダート
|
CA2556669C
(en)
|
2004-06-28 |
2012-05-01 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor peptide analogs
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
SI1778251T1
(sl)
|
2004-07-27 |
2011-07-29 |
Gilead Sciences Inc |
Nukleozidni fosfonatni konjugati kot sredstva proti HIV
|
ES2327252T3
(es)
|
2004-08-23 |
2009-10-27 |
F. Hoffmann-La Roche Ag |
4'-azido nucleosidos antivirales.
|
US7550559B2
(en)
|
2004-08-27 |
2009-06-23 |
Schering Corporation |
Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
|
WO2007001406A2
(en)
|
2004-10-05 |
2007-01-04 |
Chiron Corporation |
Aryl-containing macrocyclic compounds
|
WO2006065335A2
(en)
|
2004-10-21 |
2006-06-22 |
Merck & Co., Inc. |
Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
|
EP1827460A4
(en)
|
2004-12-09 |
2012-03-14 |
Univ Minnesota |
NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
|
EP1853618A1
(en)
|
2005-02-28 |
2007-11-14 |
Genelabs Technologies, Inc. |
Tricyclic-nucleoside compounds for treating viral infections
|
EP1858889A1
(en)
|
2005-03-08 |
2007-11-28 |
Biota Scientific Management Pty. Ltd. |
Bicyclic nucleosides and nucleotides as therapeutic agents
|
EP1898934A1
(en)
|
2005-03-09 |
2008-03-19 |
Idenix (Cayman) Limited |
Nucleosides with non-natural bases as anti-viral agents
|
AR056327A1
(es)
*
|
2005-04-25 |
2007-10-03 |
Genelabs Tech Inc |
Compuestos de nucleosidos para el tratamiento de infecciones virales
|
EP1879607B1
(en)
|
2005-05-02 |
2014-11-12 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
WO2007027248A2
(en)
|
2005-05-16 |
2007-03-08 |
Valeant Research & Development |
3', 5' - cyclic nucleoside analogues for treatment of hcv
|
US7632821B2
(en)
|
2005-08-09 |
2009-12-15 |
Merck & Co., Inc. |
Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection
|
WO2007022073A2
(en)
|
2005-08-12 |
2007-02-22 |
Merck & Co., Inc. |
Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
|
EP1928475B1
(en)
|
2005-08-15 |
2018-05-23 |
Riboscience LLC |
Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides
|
BRPI0616738A2
(pt)
|
2005-09-26 |
2011-06-28 |
Pharmasset Inc |
4'-nucleosìdeos modificados como agentes antivirais
|
CN101511375B
(zh)
|
2005-12-02 |
2012-09-05 |
耶鲁大学 |
L-胞嘧啶核苷类似物在制备用于治疗癌症和其它病症或疾病状态的药物中的应用
|
RU2422454C2
(ru)
|
2005-12-09 |
2011-06-27 |
Ф. Хоффманн-Ля Рош Аг |
Антивирусные нуклеозиды
|
US7781576B2
(en)
|
2005-12-23 |
2010-08-24 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
CA2637879A1
(en)
|
2006-02-14 |
2007-08-23 |
Merck & Co., Inc. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
EP2004634A1
(en)
|
2006-04-04 |
2008-12-24 |
F.Hoffmann-La Roche Ag |
3',5'-di-o-acylated nucleosides for hcv treatment
|
WO2008005542A2
(en)
|
2006-07-07 |
2008-01-10 |
Gilead Sciences, Inc., |
Antiviral phosphinate compounds
|
NZ575437A
(en)
|
2006-09-27 |
2012-02-24 |
Coley Pharm Gmbh |
Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
|
WO2008045419A1
(en)
|
2006-10-10 |
2008-04-17 |
Pharmasset, Inc. |
Preparation of nucleosides ribofuranosyl pyrimidines
|
DK2084175T3
(da)
|
2006-10-10 |
2011-04-18 |
Medivir Ab |
HCV nucleosidinhibitor
|
GB0623493D0
(en)
|
2006-11-24 |
2007-01-03 |
Univ Cardiff |
Chemical compounds
|
EP2102221B1
(en)
|
2006-12-11 |
2010-08-18 |
F. Hoffmann-La Roche AG |
Process for preparation of 4'-azido cytidine derivatives
|
CA2672613A1
(en)
*
|
2006-12-20 |
2008-07-03 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
|
US20080261913A1
(en)
|
2006-12-28 |
2008-10-23 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of liver disorders
|
WO2008083465A1
(en)
|
2007-01-08 |
2008-07-17 |
University Health Network |
Pyrimidine derivatives as anticancer agents
|
US8324179B2
(en)
|
2007-02-09 |
2012-12-04 |
Gilead Sciences, Inc. |
Nucleoside analogs for antiviral treatment
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
MX2009012433A
(es)
|
2007-05-14 |
2010-04-30 |
Rfs Pharma Llc |
Azido nucleosidos de purina para el tratamiento de infecciones virales.
|
US20090048189A1
(en)
|
2007-08-15 |
2009-02-19 |
Genelabs Technologies, Inc. |
Tricyclic-nucleoside compounds for treating viral infections
|
GB0718575D0
(en)
|
2007-09-24 |
2007-10-31 |
Angeletti P Ist Richerche Bio |
Nucleoside derivatives as inhibitors of viral polymerases
|
US20090318380A1
(en)
|
2007-11-20 |
2009-12-24 |
Pharmasset, Inc. |
2',4'-substituted nucleosides as antiviral agents
|
WO2009086192A1
(en)
|
2007-12-21 |
2009-07-09 |
Alios Biopharma, Inc. |
Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents
|
CN103816174B
(zh)
|
2008-04-03 |
2017-12-05 |
春堤制药公司 |
用于治疗病毒感染的化合物和方法
|
PT2937350T
(pt)
|
2008-04-23 |
2018-04-16 |
Gilead Sciences Inc |
Análogos de carba-nucleósidos 1¿-substituídos para tratamento antiviral
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
KR20110065440A
(ko)
|
2008-07-02 |
2011-06-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
바이러스 감염의 치료를 위한 화합물 및 제약 조성물
|
EP2313102A2
(en)
|
2008-07-03 |
2011-04-27 |
Biota Scientific Management |
Bycyclic nucleosides and nucleotides as therapeutic agents
|
GB0815968D0
(en)
|
2008-09-03 |
2008-10-08 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
JP2012513953A
(ja)
|
2008-09-23 |
2012-06-21 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
付加環化を用いたモノマーおよびオリゴヌクレオチドの化学修飾
|
AR074897A1
(es)
|
2008-12-23 |
2011-02-23 |
Pharmasset Inc |
Fosforamidatos de nucleosidos
|
AU2009329872B2
(en)
*
|
2008-12-23 |
2016-07-07 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
KR20110098849A
(ko)
|
2008-12-23 |
2011-09-01 |
파마셋 인코포레이티드 |
뉴클레오시드 유사체
|
US8759318B2
(en)
|
2009-01-09 |
2014-06-24 |
Inhibitex, Inc. |
Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
CN102395590A
(zh)
|
2009-02-06 |
2012-03-28 |
Rfs制药公司 |
用于治疗癌症和病毒感染的嘌呤核苷单磷酸酯前药
|
PE20161067A1
(es)
|
2009-02-10 |
2016-10-23 |
Gilead Sciences Inc |
Analogos carba-nucleosidicos para tratamiento antiviral
|
US20100240604A1
(en)
|
2009-03-20 |
2010-09-23 |
Alios Biopharma, Inc. |
Protected nucleotide analogs
|
EP2623104A1
(en)
|
2009-03-20 |
2013-08-07 |
Alios Biopharma, Inc. |
Substituted nucleoside and nucleotide analogs
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
TW201107342A
(en)
|
2009-05-20 |
2011-03-01 |
Chimerix Inc |
Compounds, compositions and methods for treating viral infection
|
US8728725B2
(en)
|
2009-07-06 |
2014-05-20 |
Trilink Biotechnologies |
Chemically modified ligase cofactors, donors and acceptors
|
US7973013B2
(en)
|
2009-09-21 |
2011-07-05 |
Gilead Sciences, Inc. |
2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
|
US8455451B2
(en)
|
2009-09-21 |
2013-06-04 |
Gilead Sciences, Inc. |
2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
|
US20100077085A1
(en)
|
2009-09-23 |
2010-03-25 |
Joseph Chyam Cohen |
Systems and method for configuring display resolution in a terminal server environment
|
BR112012007122A2
(pt)
|
2009-09-29 |
2016-07-12 |
Janssen Products Lp |
derivados de fosforamidatos de nucleosídeos
|
US8816074B2
(en)
|
2009-11-16 |
2014-08-26 |
University of Georgia Foundation, Inc. |
2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
|
EA201270632A1
(ru)
|
2009-11-16 |
2013-01-30 |
Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. |
2'-фтор-6'-метилен карбоциклические нуклеозиды и способы лечения вирусных инфекций
|
JP5675849B2
(ja)
|
2010-01-28 |
2015-02-25 |
リボサイエンス・エルエルシー |
抗−hcv化合物としての4’−アジド−ヌクレオシド
|
EP2542074A4
(en)
|
2010-03-04 |
2014-05-14 |
Enanta Pharm Inc |
PHARMACEUTICAL COMBINATION ACTIVE AGENTS AS HCV REPLICATION INHIBITORS
|
TW201139457A
(en)
|
2010-03-31 |
2011-11-16 |
Pharmasset Inc |
Stereoselective synthesis of phosphorus containing actives
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
WO2011123586A1
(en)
*
|
2010-04-01 |
2011-10-06 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
TW201201815A
(en)
|
2010-05-28 |
2012-01-16 |
Gilead Sciences Inc |
1'-substituted-carba-nucleoside prodrugs for antiviral treatment
|
US20110306541A1
(en)
|
2010-06-10 |
2011-12-15 |
Gilead Sciences, Inc. |
Methods for treating hcv
|
US9090642B2
(en)
|
2010-07-19 |
2015-07-28 |
Gilead Sciences, Inc. |
Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
|
TW201305185A
(zh)
|
2010-09-13 |
2013-02-01 |
Gilead Sciences Inc |
用於抗病毒治療之2’-氟取代之碳-核苷類似物
|
WO2012040126A1
(en)
*
|
2010-09-22 |
2012-03-29 |
Alios Biopharma, Inc. |
Substituted nucleotide analogs
|
ES2701020T3
(es)
|
2010-09-22 |
2019-02-20 |
Alios Biopharma Inc |
Nucleósidos azido y análogos nucleotídicos
|
CA2810928A1
(en)
|
2010-09-22 |
2012-03-29 |
Alios Biopharma, Inc. |
Substituted nucleotide analogs
|
WO2012048013A2
(en)
|
2010-10-06 |
2012-04-12 |
Inhibitex, Inc. |
Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
|
EP2638053B1
(en)
|
2010-11-10 |
2016-08-31 |
Janssen Products, L.P. |
Uracyl spirooxetane nucleoside phosphoramidates
|
ES2531583T3
(es)
|
2010-11-10 |
2015-03-17 |
Janssen Products, L.P. |
Fosforamidatos de espironucleósido oxetánico uracílico
|
CA2818853A1
(en)
|
2010-11-30 |
2012-06-07 |
Gilead Pharmasset Llc |
2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
|
AU2011349844B2
(en)
|
2010-12-20 |
2017-06-01 |
Gilead Sciences, Inc. |
Combinations for treating HCV
|
AU2011349278C1
(en)
*
|
2010-12-22 |
2017-01-19 |
Alios Biopharma, Inc. |
Cyclic nucleotide analogs
|
EP2658857B1
(en)
|
2010-12-29 |
2016-11-02 |
Inhibitex, Inc. |
Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
|
US9095599B2
(en)
|
2011-01-03 |
2015-08-04 |
Nanjing Molecular Research, Inc. |
O-(substituted benzyl) phosphoramidate compounds and therapeutic use
|
US9156874B2
(en)
|
2011-01-03 |
2015-10-13 |
Nanjing Molecular Research, Inc. |
Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
|
WO2012125900A1
(en)
|
2011-03-16 |
2012-09-20 |
Enanta Pharmaceuticals, Inc. |
2'-allene-substituted nucleoside derivatives
|
WO2012154321A1
(en)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
CN103476783A
(zh)
|
2011-04-13 |
2013-12-25 |
吉里德科学公司 |
用于抗病毒治疗的1’-取代的嘧啶n-核苷类似物
|
CA2832459A1
(en)
*
|
2011-04-13 |
2012-10-18 |
Merck Sharp & Dohme Corp. |
2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
WO2012142093A2
(en)
|
2011-04-13 |
2012-10-18 |
Merck Sharp & Dohme Corp. |
2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
WO2012142075A1
(en)
|
2011-04-13 |
2012-10-18 |
Merck Sharp & Dohme Corp. |
2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
KR20140033446A
(ko)
|
2011-05-19 |
2014-03-18 |
알에프에스 파마 엘엘씨 |
바이러스 감염 치료용 퓨린 모노포스페이트 프로드럭
|
EP2731433A4
(en)
|
2011-07-13 |
2014-12-31 |
Merck Sharp & Dohme |
5'-SUBSTITUTED NUCLEOSIDE ANALOGUES AND METHODS OF USE FOR THE TREATMENT OF VIRAL DISEASES
|
EP2731434A4
(en)
|
2011-07-13 |
2014-12-31 |
Merck Sharp & Dohme |
5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
|
WO2013013009A2
(en)
|
2011-07-19 |
2013-01-24 |
Nanjing Molecular Research, Inc. |
2',3'-DIDEOXY-2'-α-FLUORO-2'-β-C-METHYLNUCLEOSIDES AND PRODRUGS THEREOF
|
EP2755983B1
(en)
|
2011-09-12 |
2017-03-15 |
Idenix Pharmaceuticals LLC. |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
EP2755985B1
(en)
|
2011-09-12 |
2017-11-01 |
Idenix Pharmaceuticals LLC |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US8575119B2
(en)
|
2011-09-23 |
2013-11-05 |
Enanta Pharmaceuticals, Inc. |
2′-chloroacetylenyl substituted nucleoside derivatives
|
WO2013056046A1
(en)
|
2011-10-14 |
2013-04-18 |
Idenix Pharmaceuticals, Inc. |
Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
WO2013084165A1
(en)
|
2011-12-05 |
2013-06-13 |
Medivir Ab |
Hcv polymerase inhibitors
|
LT2794628T
(lt)
|
2011-12-20 |
2017-07-10 |
Riboscience Llc |
4`-azido-3`-fluoro pakeistieji nukleozido dariniai kaip hcv replikacijos inhibitoriai
|
SI2794629T1
(sl)
|
2011-12-20 |
2017-10-30 |
Riboscience Llc |
2'4'-difluoro-2'-metil substituirani nukleozidni derivati k0t zaviralci replikacije hcv-rna
|
WO2013106344A1
(en)
|
2012-01-12 |
2013-07-18 |
Ligand Pharmaceuticals, Inc. |
2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
|
US9296778B2
(en)
|
2012-05-22 |
2016-03-29 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphate prodrugs for HCV infection
|
MX355708B
(es)
|
2012-05-22 |
2018-04-27 |
Idenix Pharmaceuticals Llc |
Compuestos de d-aminoacidos para enfermedades del higado.
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
EP2900682A1
(en)
|
2012-09-27 |
2015-08-05 |
IDENIX Pharmaceuticals, Inc. |
Esters and malonates of sate prodrugs
|
US10513534B2
(en)
|
2012-10-08 |
2019-12-24 |
Idenix Pharmaceuticals Llc |
2′-chloro nucleoside analogs for HCV infection
|
AR092959A1
(es)
|
2012-10-17 |
2015-05-06 |
Merck Sharp & Dohme |
Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
|
WO2014059902A1
(en)
|
2012-10-17 |
2014-04-24 |
Merck Sharp & Dohme Corp. |
2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
|
WO2014059901A1
(en)
|
2012-10-17 |
2014-04-24 |
Merck Sharp & Dohme Corp. |
2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
|
WO2014063019A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
US20140205566A1
(en)
|
2012-11-30 |
2014-07-24 |
Novartis Ag |
Cyclic nucleuoside derivatives and uses thereof
|
US9211300B2
(en)
|
2012-12-19 |
2015-12-15 |
Idenix Pharmaceuticals Llc |
4′-fluoro nucleosides for the treatment of HCV
|
WO2014124430A1
(en)
|
2013-02-11 |
2014-08-14 |
Emory University |
Nucleotide and nucleoside therapeutic compositions and uses related thereto
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
EP2970357A1
(en)
|
2013-03-13 |
2016-01-20 |
IDENIX Pharmaceuticals, Inc. |
Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
|
RU2534613C2
(ru)
|
2013-03-22 |
2014-11-27 |
Александр Васильевич Иващенко |
Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
|
CN103848876B
(zh)
|
2013-03-25 |
2016-05-11 |
安徽贝克联合制药有限公司 |
一种核苷磷酰胺前药及其制备方法和其应用
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
WO2014197578A1
(en)
|
2013-06-05 |
2014-12-11 |
Idenix Pharmaceuticals, Inc. |
1',4'-thio nucleosides for the treatment of hcv
|
WO2014204831A1
(en)
|
2013-06-18 |
2014-12-24 |
Merck Sharp & Dohme Corp. |
Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
WO2015066370A1
(en)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
WO2015077360A2
(en)
|
2013-11-20 |
2015-05-28 |
Idenix Pharmaceuticals, Inc. |
Cyclopentane and cyclopentene nucleoside analogs for the treatment of hcv
|
WO2015081133A2
(en)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals, Inc. |
Nucleotides for the treatment of liver cancer
|
EP3074399A1
(en)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
CN103848877B
(zh)
|
2013-12-16 |
2016-08-24 |
安徽贝克联合制药有限公司 |
核苷环磷酸酯化合物及其制备方法和其应用
|
WO2015095305A1
(en)
|
2013-12-17 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
Production of cyclic phosphate, phosphoramidate, thiophosphate, and phosphonate nucleoside compounds
|
US10683321B2
(en)
|
2013-12-18 |
2020-06-16 |
Idenix Pharmaceuticals Llc |
4′-or nucleosides for the treatment of HCV
|
WO2015134780A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
|
EP3131914B1
(en)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|